**Traders see only a 7% chance of a new WHO-designated COVID variant of concern before 2027, reflecting the current stable global picture.** As of mid-2026, no SARS-CoV-2 lineages meet VOC criteria for significantly increased transmissibility, severity, or immune escape, according to ECDC and WHO tracking. Subvariants such as BA.3.2 (first noted in late 2024 and rising in parts of Europe by early 2026) and others like XFG or NB.1.8.1 remain under monitoring or of interest only, with low overall prevalence and no major impact on hospitalizations. Ongoing genomic surveillance shows continued Omicron sublineage circulation without the dramatic shifts seen in prior years, and updated vaccines plus population immunity keep severe outcomes in check. With just five months left in the period, the lack of fresh concerning signals supports the strong trader consensus on “No.”
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$243,750 Vol.
$243,750 Vol.
$243,750 Vol.
$243,750 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Pasar Dibuka: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...**Traders see only a 7% chance of a new WHO-designated COVID variant of concern before 2027, reflecting the current stable global picture.** As of mid-2026, no SARS-CoV-2 lineages meet VOC criteria for significantly increased transmissibility, severity, or immune escape, according to ECDC and WHO tracking. Subvariants such as BA.3.2 (first noted in late 2024 and rising in parts of Europe by early 2026) and others like XFG or NB.1.8.1 remain under monitoring or of interest only, with low overall prevalence and no major impact on hospitalizations. Ongoing genomic surveillance shows continued Omicron sublineage circulation without the dramatic shifts seen in prior years, and updated vaccines plus population immunity keep severe outcomes in check. With just five months left in the period, the lack of fresh concerning signals supports the strong trader consensus on “No.”
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui



Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan